Trial Profile
A randomized, double-blind, single and multiple ascending dose phase I trial of Tobrate in healthy volunteers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2016
Price :
$35
*
At a glance
- Drugs Tobramycin (Primary)
- Indications Urinary tract infections
- Focus Adverse reactions; Pharmacokinetics
- 13 Jul 2016 According to an Enteris BioPharna media release, data from this trail is expected in the first quarter of 2017.
- 13 Jul 2016 According to an Enteris BioPharna media release, the US FDA has accepted an Investigational New Drug (IND) application for Tobrate clinical program.
- 13 Jul 2016 According to an Enteris BioPharna media release, status changed from planning to not yet recruiting.